Upadacitinib for treatment-resistant Lichen amyloidosis

J Eur Acad Dermatol Venereol. 2023 May;37(5):e633-e635. doi: 10.1111/jdv.18756. Epub 2022 Nov 26.

Authors

Farzan Solimani^{1

2}, Amrei Dilling¹, Franziska C Ghoreschi¹, Alexander Nast¹, Kamran Ghoreschi¹, Katharina Meier¹

Affiliations

¹ Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
² Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany.

PMID: 36394121
DOI: 10.1111/jdv.18756

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Amyloidosis, Familial*
Heterocyclic Compounds, 3-Ring
Humans
Skin Diseases, Genetic*

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring

Supplementary concepts

Amyloidosis, Primary Cutaneous

Grants and funding